论文部分内容阅读
2012年9月19日,美国食品和药品管理局(FDA)发布公告:普拉克索可能增加心力衰竭的风险,FDA正在对此进行风险评估[1]。普拉克索是多巴胺受体激动剂,可替代由脑特定区域产生的控制运动的多巴胺。由于帕金森病可导致脑中多巴胺生成进行性减少,故普拉克索可用于治疗帕金森病和不宁腿综合征。
On September 19, 2012, the U.S. Food and Drug Administration (FDA) issued a public notice: Pramipexole may increase the risk of heart failure, and the FDA is conducting a risk assessment [1]. Pramipexole, a dopamine receptor agonist, is an alternative to exercise-controlling dopamine produced in specific areas of the brain. Because Parkinson’s disease can cause a progressive decrease in dopamine production in the brain, pramipexole can be used to treat Parkinson’s disease and restless legs syndrome.